

New York State Oncology - Molecular Detection Proficiency Test - October 2007 (2007-3)
Summary of results

| Sample | NYS#L/L 1 (10-07) | | | | Overall diagnosis: T-cell clone (TcRBeta and TcRGamma rearrangements) with IgH rearrangement | | | | | | | | | | | | | | | | | | | | |
|--|-------------------|---|-----|------|--|----|-----|------|--------|---|-----|------|------|---|-----|------|-------------|----|-------|----------------------------------|-------------------------------------|---------------------------------------|--|-----------------------|--|
| | SB | | | | PCR | | | | RT-PCR | | | | FISH | | | | All methods | | | | Method used | | RT-PCR (qualitative) | RT-PCR (quantitative) | FISH |
| | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | Cons | SB | PCR | | | | |
| Ig H | 5 | | | R | 1 | 27 | | G | | | | I | 1 | 1 | | I | 7 | 28 | R/G/I | Dako (3), home brew (2) | Biomed (8), home brew (15), IVS (5) | | | | Vysis (1), unk (1) |
| Ig kappa | | 3 | | G | | 7 | | G | | | | I | | | | I | 0 | 10 | G | Dako (1), home brew (2) | Biomed (3), home brew(2), IVS (2) | | | | |
| Ig lambda | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | I | home brew (1) | home brew (1) | | | | |
| TcR beta | 3 | 4 | | I | 6 | 1 | | R | | | | I | | | | I | 9 | 5 | I/R | home brew (3), Dako (3), unk (1) | Biomed (5), home brew (2) | | | | |
| TcR gamma | | | | I | 24 | | | R | | | | I | | | | I | 24 | 0 | R | | Biomed (4), home brew (17), IVS (3) | | | | |
| TcR delta | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | I | home brew (1) | home brew (1) | | | | |
| Bcl2 t(14;18) MBR | | 1 | | I | | 13 | | G | | | | I | | | | I | 0 | 14 | G | home brew (1) | Biomed (2), IVS (1), home brew (10) | | | | |
| mcr | | | | I | | 11 | | G | | | | I | | | | I | 0 | 11 | G | | Biomed (2), IVS (1), home brew (8) | | | | |
| MBR 3' | | | | I | | 2 | | G | | | | I | | | | I | 0 | 2 | G | | Biomed (2) | | | | |
| MBR/mcr | | | | I | | | | I | | | | I | | 2 | | G | 0 | 2 | G | | | | | | Vysis (2), unk (1) |
| Bcl1 t(11;14) | | 1 | | I | | 6 | | G | | | | I | | 2 | | G | 0 | 9 | G | home brew (1) | home brew (5), other (1) | | | | Vysis (1), unk (1) |
| Bcr/abl t(9;22) p210 | | 1 | | I | | 4 | | G | 20 | | | G | | | | I | 0 | 25 | G | home brew (1) | home brew (3), Ipsogen (1) | home brew (4) | Ipsogen (3), home brew (12), other (1) | | |
| p190 | | | | I | | 3 | | G | 16 | | | G | | | | I | 0 | 19 | G | | home brew (3) | home brew (5) | Ipsogen (3), home brew (8) | | |
| p210/190 | | | | I | | 1 | | I | 5 | | | G | 3 | | | G | 0 | 9 | G | home brew (1) | Roche (2) | Ipsogen (1), home brew (1), Roche (1) | | | Vysis (2), unk (1) |
| Abl kinase domain mutation | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | I | | | Sequencing (1) | | | |
| PML/RARa Long | | | | I | | 2 | | G | 10 | | | G | | | | I | 0 | 12 | G | | home brew (2) | home brew (5) | home brew (5) | | |
| Short | | | | I | | 2 | | G | 9 | | | G | | | | I | 0 | 11 | G | | home brew (4) | home brew (5) | | | |
| Variable | | | | I | | 1 | | I | 4 | | | G | | | | I | 0 | 5 | G | | home brew (1) | home brew (3) | home brew (1) | | |
| Long/Short/Variable | | | | I | | | | I | 1 | | | I | 2 | | | G | 0 | 3 | G | | home brew (1) | | | | Vysis (1), unk (1) |
| c-myc t(8;14) | | | | I | | | | I | | | | I | 2 | | | G | 0 | 2 | G | | | | | | Vysis (1), unk (1) |
| AML1/ETO t(8;21) | | | | I | | 1 | | I | 6 | | | G | 2 | | | G | 0 | 9 | G | | home brew (1) | home brew (4) | home brew (2) | | Vysis (1), unk (1) |
| NPM/ALK t(2;5) | | | | I | | | | I | 1 | | | I | 1 | | | I | 0 | 2 | I | | home brew (1) | | | | Vysis (1) |
| TEL/AML1 t(12;21) | | | | I | | | | I | 3 | | | G | 2 | | | G | 0 | 5 | G | | home brew (2) | home brew (1) | | | Vysis (1), unk (1) |
| EBV | | | | I | 1 | 3 | | G | | | | I | | | | I | 1 | 3 | G | | Roche (1), home brew (2), other (1) | home brew (4) | | | |
| KSHV/HHV8 | | | | I | | 4 | | G | | | | I | | | | I | 0 | 4 | G | | | | | | |
| HTLV1 | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | | |
| CBFB INV(16) | | | | I | | | | I | 4 | | | G | 2 | | | G | 0 | 6 | G | | home brew (3) | home brew (1) | | | Vysis (1), unk (1) |
| E2A-PBX t(1;19) | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | I | | home brew (1) | | | | |
| MLL (11q23) | | | | I | | | | I | 2 | | | G | 2 | | | G | 0 | 4 | G | | home brew (2) | | | | Vysis (1), unk (1) |
| JAK2 (V617F) | | | | I | | 18 | | G | 3 | | | G | 1 | | | I | 0 | 22 | G | | IVS(3), Ips(1), home brew(14) | home brew (2) | home brew (1) | | IVS (1) |
| FLT3 ITD | | | | I | | 13 | | G | | | | I | | | | I | 0 | 13 | G | | IVS (2), home brew (11) | | | | |
| FLT3 D835 | | | | I | | 11 | | G | | | | I | | | | I | 0 | 11 | G | | IVS (2), home brew (9) | | | | |
| P53 | | | | I | 1 | 1 | | I | | | | I | 2 | | | G | 1 | 3 | I/G | | home brew (2) | | | | Vysis (1), unk (1) |
| IgV _H mutation | | | | I | | 1 | | I | 2 | | | G | | | | I | 0 | 3 | G | | home brew (1) | home brew (1), unk (1) | | | |
| c-kit | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | | |
| BCL-6 | | | | I | | | | I | | | | I | 2 | | | G | 0 | 2 | G | | | | | | Vysis (1), unk (1) |
| Other: NPM1, RARA, MLK, ALK, ATM(2), CEP12 | | | | I | | 1 | | I | | | | I | 6 | | | I | 0 | 7 | I | | home brew (1) NPM1 | | | | Vysis for ATM & CEP12 (1), unk for RARA, MLK & ALK (1) |

New York State Oncology - Molecular Detection Proficiency Test - October 2007 (2007-3)
Summary of results

| Sample | NYS#L/L 2 (10-07) | | | | | | | | | | | | | | | | Overall diagnosis: B cell clone with presence of EBV | | | | | | | |
|--|-------------------|---|-----|------|-----|----|-----|------|--------|---|-----|------|------|---|-----|------|--|----|-------|----------------------------------|-------------------------------------|------------------------|--|--|
| | SB | | | | PCR | | | | RT-PCR | | | | FISH | | | | All methods | | | Method used | | RT-PCR (qualitative) | RT-PCR (quantitative) | FISH |
| | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | Cons | SB | PCR | | | |
| Ig H | 6 | | | R | 28 | | | R | | | | I | 1 | 1 | | I | 35 | 1 | R/R/I | Dako (4), home brew (2) | Biomed (8), home brew (15), IVS (5) | | | Vysis (1), unk (1) |
| Ig kappa | 3 | | | R | 6 | 1 | | R | | | | I | | | | I | 9 | 1 | R | Dako (1), home brew (2) | Biomed (3), home brew (2), IVS (2) | | | |
| Ig lambda | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | I | home brew (1) | home brew (1) | | | |
| TcR beta | | 7 | | G | 2 | 5 | | G | | | | I | | | | I | 2 | 12 | G | home brew (3), Dako (3), unk (1) | Biomed (5), home brew (2) | | | |
| TcR gamma | | | | I | 8 | 14 | 2 | G | | | | I | | | | I | 8 | 14 | G | | Biomed (4), home brew (17), IVS (3) | | | |
| TcR delta | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | I | home brew (1) | home brew (1) | | | |
| Bcl2 t(14;18) MBR | | 1 | | I | | 13 | | G | | | | I | | | | I | 0 | 14 | G | home brew (1) | Biomed (2), IVS (1), home brew (10) | | | |
| mcr | | | | I | | 11 | | G | | | | I | | | | I | 0 | 11 | G | | Biomed (2), IVS (1), home brew (8) | | | |
| MBR 3' | | | | I | | 2 | | G | | | | I | | | | I | 0 | 2 | G | | Biomed (2) | | | |
| MBR/mcr | | | | I | | | | I | | | | I | | 3 | | G | 0 | 3 | G | | | | | Vysis (2), unk (1) |
| Bcl1 t(11;14) | | 1 | | I | | 6 | | G | | | | I | | 3 | | G | 0 | 10 | G | home brew (1) | home brew (5), other (1) | | | Vysis (2), unk (1) |
| Bcr/abl t(9;22) p210 | | 1 | | I | | 4 | | G | 20 | | | G | | | | I | 0 | 25 | G | home brew (1) | home brew (3), Ipsogen | home brew (4) | Ipsogen (3), home brew (12), other (1) | |
| p190 | | | | I | | 3 | | G | 16 | | | G | | | | I | 0 | 19 | G | | home brew (3) | home brew (5) | Ipsogen (3), home brew (8) | |
| p210/190 | | | | I | | 1 | | I | 5 | | | G | 4 | | | G | 0 | 10 | G | | home brew (1) | Roche (2) | Ipsogen (1), home brew (1), Roche (1) | Vysis (3), unk (1) |
| Abl kinase domain mutation | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | I | | | Sequencing | | |
| PML/RARa Long | | | | I | | 2 | | G | 10 | | | G | | | | I | 0 | 12 | G | | home brew (2) | home brew (5) | home brew (5) | |
| Short | | | | I | | 2 | | G | 9 | | | G | | | | I | 0 | 11 | G | | | home brew (4) | home brew (5) | |
| Variable | | | | I | | 1 | | I | 4 | | | G | | | | I | 0 | 5 | G | | home brew (1) | home brew (3) | home brew (1) | |
| Long/Short/Variable | | | | I | | | | I | 1 | | | I | 2 | | | G | 0 | 3 | G | | | home brew (1) | | Vysis (1), unk (1) |
| c-myc t(8;14) | | | | I | | | | I | | | | I | 3 | | | G | 0 | 3 | G | | | | | Vysis (2), unk (1) |
| AML1/ETO t(8;21) | | | | I | | 1 | | I | 6 | | | G | 2 | | | G | 0 | 9 | G | | home brew (1) | home brew (4) | home brew (2) | Vysis (1), unk (1) |
| NPM/ALK t(2;5) | | | | I | | | | I | 1 | | | I | 1 | | | I | 0 | 2 | I | | | home brew (1) | | Vysis (1) |
| TEL/AML1 t(12;21) | | | | I | | | | I | 3 | | | G | 2 | | | G | 0 | 5 | G | | | home brew (2) | home brew (1) | Vysis (1), unk (1) |
| EBV | | | | I | 4 | | | R | | | | I | | | | I | 4 | 0 | R | | Roche (1), home brew (2), other (1) | | | |
| KSHV/HHV8 | | | | I | | 4 | | G | | | | I | | | | I | 0 | 4 | G | | | home brew (4) | | |
| HTLV1 | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | G | | | home brew (3) | | |
| CBFB INV(16) | | | | I | | | | I | 4 | | | G | 2 | | | G | 0 | 6 | G | | | home brew (3) | home brew (1) | Vysis (1), unk (1) |
| E2A-PBX t(1;19) | | | | I | | | | I | 1 | | | I | | | | I | 0 | 1 | I | | | home brew (1) | | |
| MLL (11q23) | | | | I | | | | I | 2 | | | G | 2 | | | G | 0 | 4 | G | | | home brew (2) | | Vysis (1), unk (1) |
| JAK2 (V617F) | | | | I | | 18 | | G | 3 | | | G | 1 | | | I | 0 | 22 | G | | IVS(3), Ips(1), home brew(14) | home brew (2) | home brew (1) | IVS (1) |
| FLT3 ITD | | | | I | | 13 | | G | | | | I | | | | I | 0 | 13 | G | | IVS (2), home brew (11) | | | |
| FLT3 D835 | | | | I | | 11 | | G | | | | I | | | | I | 0 | 11 | G | | IVS (2), home brew (9) | | | |
| P53 | | | | I | | 2 | | G | | | | I | 2 | | | G | 0 | 4 | G | | home brew (2) | | | Vysis (1), unk (1) |
| IgV _H mutation | | | | I | | 3 | | G | 2 | | | G | | | | I | 0 | 5 | G | | home brew (3) | home brew (1), unk (1) | | |
| c-kit | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | |
| BCL-6 | | | | I | | | | I | | | | I | 3 | | | G | 0 | 3 | G | | | | | Vysis (2), unk (1) |
| Other: NPM1, RARA, MLK, ALK, ATM(2), CEP12 | | | | I | | 1 | | I | | | | I | 6 | | | I | 0 | 7 | I | | home brew (1) NPM1 | | | Vysis for ATM & CEP12 (1), unk for RARA, MLK & ALK (1) |

New York State Oncology - Molecular Detection Proficiency Test - October 2007 (2007-3)
Summary of results

| Sample | NYS#L/L 3 (10-07) | | | | | | | | | | | | | | | | Overall diagnosis: CML with bcr/abl MBR translocation | | | | | | | |
|--|-------------------|---|-----|------|-----|----|-----|------|--------|----|-----|------|------|---|-----|------|---|----|------|----------------------------------|-------------------------------------|------------------------|--|---|
| | SB | | | | PCR | | | | RT-PCR | | | | FISH | | | | All methods | | | Method used | | RT-PCR (qualitative) | RT-PCR (quantitative) | FISH |
| | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | ind | Cons | R | G | Cons | SB | PCR | | | |
| Ig H | | 6 | | G | | 27 | 1 | G | | | | I | | 2 | | G | 0 | 35 | G | Dako (4), home brew (2) | Biomed (8), home brew (15), IVS (5) | | | Vysis (1), unk (1) |
| Ig kappa | | 3 | | G | | 7 | | G | | | | I | | | | I | 0 | 10 | G | Dako (1), home brew (2) | Bimed (3), home brew (2), IVS (2) | | | |
| Ig lambda | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | I | home brew (1) | home brew (1) | | | |
| TcR beta | | 7 | | G | | 2 | 5 | G | | | | I | | | | I | 2 | 12 | G | home brew (3), Dako (3), unk (1) | Biomed (5), home brew (2) | | | |
| TcR gamma | | | | I | | 4 | 20 | G | | | | I | | | | I | 4 | 20 | G | | Biomed (4), home brew (17), IVS (3) | | | |
| TcR delta | | 1 | | I | | 1 | | I | | | | I | | | | I | 0 | 2 | I | home brew (1) | home brew (1) | | | |
| Bcl2 t(14;18) MBR | | 1 | | I | | 1 | 12 | G | | | | I | | | | I | 1 | 13 | G | home brew (1) | Biomed (2), IVS (1), home brew (10) | | | |
| mcr | | | | I | | | 11 | G | | | | I | | | | I | 0 | 11 | G | | Biomed (2), IVS (1), home brew (8) | | | |
| MBR 3' | | | | I | | | 2 | G | | | | I | | | | I | 0 | 2 | G | | Biomed (2) | | | |
| MBR/mcr | | | | I | | | | I | | | | I | | 2 | | G | 0 | 2 | G | | | | | Vysis (1), unk (1) |
| Bcl1 t(11;14) | | 1 | | I | | 6 | | G | | | | I | | 2 | | G | 0 | 9 | G | home brew (1) | home brew (5), other (1) | | | Vysis (1), unk (1) |
| Bcr/abl t(9;22) p210 | 1 | | | I | 3 | 1 | | R | 19 | | | R | | | | I | 23 | 1 | R | home brew (1) | home brew (3), Ipsogen (1) | home brew (4) | Ipsogen (3), home brew (11), other (1) | Ipsogen (3), home brew (7) |
| p190 | | | | I | 1 | 1 | | I | 7 | 7 | | I | | | | I | 8 | 8 | I | | home brew (2) | home brew (4) | | |
| p210/190 | | | | I | | | | I | 6 | | | R | 4 | 1 | | R | 10 | 1 | R | | | Roche (2) | Ipsogen (1), home brew (2), roche (1) | Vysis (3), unk (1) |
| Abl kinase domain mutation | | | | I | | 2 | | G | | 2 | | G | | | | I | 0 | 4 | G | | PCR/sequencing (2) | RT-PCR/sequencing (2) | | |
| PML/RARa Long | | | | I | | 2 | | G | | 10 | | G | | | | I | 0 | 12 | G | | home brew (2) | home brew (5) | home brew (5) | |
| Short | | | | I | | 2 | | G | | 9 | | G | | | | I | 0 | 11 | G | | | home brew (4) | home brew (5) | |
| Variable | | | | I | | 1 | | I | | 3 | | G | | | | I | 0 | 4 | G | | home brew (1) | home brew (2) | home brew (1) | |
| Long/Short/Variable | | | | I | | | | I | | 1 | | I | | 3 | | G | 0 | 4 | G | | | home brew (1) | | Vysis (2), unk (1) |
| c-myc t(8;14) | | | | I | | | | I | | | | I | | 2 | | G | 0 | 2 | G | | | | | Vysis (1), unk (1) |
| AML1/ETO t(8;21) | | | | I | | 1 | | I | | 6 | | G | | 3 | | G | 0 | 10 | G | | home brew (1) | home brew (4) | home brew (2) | Vysis (2), unk (1) |
| NPM/ALK t(2;5) | | | | I | | | | I | | 1 | | I | | 1 | | I | 0 | 2 | I | | | home brew (1) | | Vysis (1) |
| TEL/AML1 t(12;21) | | | | I | | | | I | | 3 | | G | | 2 | | G | 0 | 5 | G | | | home brew (2) | home brew (1) | Vysis (1), unk (1) |
| EBV | | | | I | | 4 | | G | | | | I | | | | I | 0 | 4 | G | | Roche (1), home brew (2), other (1) | | | |
| KSHV/HHV8 | | | | I | | 4 | | G | | | | I | | | | I | 0 | 4 | G | | | home brew (4) | | |
| HTLV1 | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | G | | | home brew (3) | | |
| CBFB INV(16) | | | | I | | | | I | | 4 | | G | | 3 | | G | 0 | 7 | G | | | home brew (3) | home brew (1) | Vysis (2), unk (1) |
| E2A-PBX t(1;19) | | | | I | | | | I | | 1 | | I | | | | I | 0 | 1 | I | | | home brew (1) | | |
| MLL (11q23) | | | | I | | | | I | | 2 | | G | | 3 | | G | 0 | 5 | G | | | home brew (2) | | Vysis (2), unk (1) |
| JAK2 (V617F) | | | | I | | 19 | | G | | 3 | | G | | 1 | | I | 0 | 23 | G | | IVS(3), Ips(1), home brew(15) | home brew (2) | home brew (1) | IVS (1) |
| FLT3 ITD | | | | I | | 14 | | G | | | | I | | | | I | 0 | 14 | G | | IVS (2), home brew (12) | | | |
| FLT3 D835 | | | | I | | 12 | | G | | | | I | | | | I | 0 | 12 | G | | IVS (2), home brew (10) | | | |
| P53 | | | | I | | 2 | | G | | | | I | | 2 | | G | 0 | 4 | G | | home brew (2) | | | Vysis (1), unk (1) |
| IgV _H mutation | | | | I | | 1 | | I | | 2 | | G | | | | I | 0 | 3 | G | | home brew (1) | home brew (1), unk (1) | | |
| c-kit | | | | I | | 3 | | G | | | | I | | | | I | 0 | 3 | G | | home brew (3) | | | |
| BCL-6 | | | | I | | | | I | | | | I | | 2 | | G | 0 | 2 | G | | | | | Vysis (1), unk (1) |
| Other: NPM1, RARA, MLK, ALK, ATM(2), CEP12, +8, -5/5q, -7/7q, -20q | | | | I | | 1 | | I | | | | I | 3 | 7 | | I | 3 | 8 | I | | home brew (1) NPM1 | | | [ATM, CEP12, +8, -5/5q, -7/7q, -20q] Vysis(1), [RARA, MLK & ALK] unk(1) |